The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global C-MET & HGF Inhibitors Market Research Report 2025
Synopsis
c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).
The global C-MET & HGF Inhibitors market was valued at US$ 2294.7 million in 2023 and is anticipated to reach US$ 10450 million by 2030, witnessing a CAGR of 23.9% during the forecast period 2024-2030.
There are three kinds of C-MET / HGF Inhibitors, which are Cabozantinib, Crizotinib and Others. Cabozantinib hold the largest share of the C-MET / HGF Inhibitors market, with a revenue market share nearly 66% in 2019.
C-MET / HGF Inhibitors is sold through Hospitals and Drugs Store. The most proportion of C-MET / HGF Inhibitors is sold through Hospitals, and the market share in 2019 is about 77%.
North America is the largest consumption place, with a consumption market share nearly 60% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of about 34%.
Shandong Exelixis, Ipsen, Pfizer, etc. are the leader of the industry, and top 3 players hold about 100% revenue market share.
This report aims to provide a comprehensive presentation of the global market for C-MET & HGF Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding C-MET & HGF Inhibitors.
Report Scope
The C-MET & HGF Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global C-MET & HGF Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the C-MET & HGF Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Exelixis
Ipsen
Pfizer
Novartis
Takeda
Merck KGaA
Merck
Daiichi Sankyo
GSK
Bristol-Myers Squibb(BMS)
Roche
AVEO Pharmaceuticals
Amgen
AstraZeneca
Mirati Therapeutics
Eli Lilly
Johnson & Johnson
Eisai
Hutchison MediPharma
Kringle Pharmaceuticals
Segment by Type
Cabozantinib
Crizotinib
Others
Segment by Application
Hospital
Drug Store
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of C-MET & HGF Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of C-MET & HGF Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).
The global C-MET & HGF Inhibitors market was valued at US$ 2294.7 million in 2023 and is anticipated to reach US$ 10450 million by 2030, witnessing a CAGR of 23.9% during the forecast period 2024-2030.
There are three kinds of C-MET / HGF Inhibitors, which are Cabozantinib, Crizotinib and Others. Cabozantinib hold the largest share of the C-MET / HGF Inhibitors market, with a revenue market share nearly 66% in 2019.
C-MET / HGF Inhibitors is sold through Hospitals and Drugs Store. The most proportion of C-MET / HGF Inhibitors is sold through Hospitals, and the market share in 2019 is about 77%.
North America is the largest consumption place, with a consumption market share nearly 60% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of about 34%.
Shandong Exelixis, Ipsen, Pfizer, etc. are the leader of the industry, and top 3 players hold about 100% revenue market share.
This report aims to provide a comprehensive presentation of the global market for C-MET & HGF Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding C-MET & HGF Inhibitors.
Report Scope
The C-MET & HGF Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global C-MET & HGF Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the C-MET & HGF Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Exelixis
Ipsen
Pfizer
Novartis
Takeda
Merck KGaA
Merck
Daiichi Sankyo
GSK
Bristol-Myers Squibb(BMS)
Roche
AVEO Pharmaceuticals
Amgen
AstraZeneca
Mirati Therapeutics
Eli Lilly
Johnson & Johnson
Eisai
Hutchison MediPharma
Kringle Pharmaceuticals
Segment by Type
Cabozantinib
Crizotinib
Others
Segment by Application
Hospital
Drug Store
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of C-MET & HGF Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of C-MET & HGF Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 C-MET & HGF Inhibitors Market Overview
1.1 Product Overview and Scope of C-MET & HGF Inhibitors
1.2 C-MET & HGF Inhibitors Segment by Type
1.2.1 Global C-MET & HGF Inhibitors Market Value Comparison by Type (2024-2030)
1.2.2 Cabozantinib
1.2.3 Crizotinib
1.2.4 Others
1.3 C-MET & HGF Inhibitors Segment by Application
1.3.1 Global C-MET & HGF Inhibitors Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Drug Store
1.4 Global C-MET & HGF Inhibitors Market Size Estimates and Forecasts
1.4.1 Global C-MET & HGF Inhibitors Revenue 2019-2030
1.4.2 Global C-MET & HGF Inhibitors Sales 2019-2030
1.4.3 Global C-MET & HGF Inhibitors Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 C-MET & HGF Inhibitors Market Competition by Manufacturers
2.1 Global C-MET & HGF Inhibitors Sales Market Share by Manufacturers (2019-2024)
2.2 Global C-MET & HGF Inhibitors Revenue Market Share by Manufacturers (2019-2024)
2.3 Global C-MET & HGF Inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global C-MET & HGF Inhibitors Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of C-MET & HGF Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of C-MET & HGF Inhibitors, Product Type & Application
2.7 C-MET & HGF Inhibitors Market Competitive Situation and Trends
2.7.1 C-MET & HGF Inhibitors Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest C-MET & HGF Inhibitors Players Market Share by Revenue
2.7.3 Global C-MET & HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 C-MET & HGF Inhibitors Retrospective Market Scenario by Region
3.1 Global C-MET & HGF Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global C-MET & HGF Inhibitors Global C-MET & HGF Inhibitors Sales by Region: 2019-2030
3.2.1 Global C-MET & HGF Inhibitors Sales by Region: 2019-2024
3.2.2 Global C-MET & HGF Inhibitors Sales by Region: 2025-2030
3.3 Global C-MET & HGF Inhibitors Global C-MET & HGF Inhibitors Revenue by Region: 2019-2030
3.3.1 Global C-MET & HGF Inhibitors Revenue by Region: 2019-2024
3.3.2 Global C-MET & HGF Inhibitors Revenue by Region: 2025-2030
3.4 North America C-MET & HGF Inhibitors Market Facts & Figures by Country
3.4.1 North America C-MET & HGF Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America C-MET & HGF Inhibitors Sales by Country (2019-2030)
3.4.3 North America C-MET & HGF Inhibitors Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe C-MET & HGF Inhibitors Market Facts & Figures by Country
3.5.1 Europe C-MET & HGF Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe C-MET & HGF Inhibitors Sales by Country (2019-2030)
3.5.3 Europe C-MET & HGF Inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific C-MET & HGF Inhibitors Market Facts & Figures by Country
3.6.1 Asia Pacific C-MET & HGF Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific C-MET & HGF Inhibitors Sales by Country (2019-2030)
3.6.3 Asia Pacific C-MET & HGF Inhibitors Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America C-MET & HGF Inhibitors Market Facts & Figures by Country
3.7.1 Latin America C-MET & HGF Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America C-MET & HGF Inhibitors Sales by Country (2019-2030)
3.7.3 Latin America C-MET & HGF Inhibitors Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa C-MET & HGF Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa C-MET & HGF Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa C-MET & HGF Inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa C-MET & HGF Inhibitors Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global C-MET & HGF Inhibitors Sales by Type (2019-2030)
4.1.1 Global C-MET & HGF Inhibitors Sales by Type (2019-2024)
4.1.2 Global C-MET & HGF Inhibitors Sales by Type (2025-2030)
4.1.3 Global C-MET & HGF Inhibitors Sales Market Share by Type (2019-2030)
4.2 Global C-MET & HGF Inhibitors Revenue by Type (2019-2030)
4.2.1 Global C-MET & HGF Inhibitors Revenue by Type (2019-2024)
4.2.2 Global C-MET & HGF Inhibitors Revenue by Type (2025-2030)
4.2.3 Global C-MET & HGF Inhibitors Revenue Market Share by Type (2019-2030)
4.3 Global C-MET & HGF Inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global C-MET & HGF Inhibitors Sales by Application (2019-2030)
5.1.1 Global C-MET & HGF Inhibitors Sales by Application (2019-2024)
5.1.2 Global C-MET & HGF Inhibitors Sales by Application (2025-2030)
5.1.3 Global C-MET & HGF Inhibitors Sales Market Share by Application (2019-2030)
5.2 Global C-MET & HGF Inhibitors Revenue by Application (2019-2030)
5.2.1 Global C-MET & HGF Inhibitors Revenue by Application (2019-2024)
5.2.2 Global C-MET & HGF Inhibitors Revenue by Application (2025-2030)
5.2.3 Global C-MET & HGF Inhibitors Revenue Market Share by Application (2019-2030)
5.3 Global C-MET & HGF Inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Exelixis
6.1.1 Exelixis Corporation Information
6.1.2 Exelixis Description and Business Overview
6.1.3 Exelixis C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Exelixis C-MET & HGF Inhibitors Product Portfolio
6.1.5 Exelixis Recent Developments/Updates
6.2 Ipsen
6.2.1 Ipsen Corporation Information
6.2.2 Ipsen Description and Business Overview
6.2.3 Ipsen C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Ipsen C-MET & HGF Inhibitors Product Portfolio
6.2.5 Ipsen Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Pfizer C-MET & HGF Inhibitors Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis C-MET & HGF Inhibitors Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Takeda
6.5.1 Takeda Corporation Information
6.5.2 Takeda Description and Business Overview
6.5.3 Takeda C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Takeda C-MET & HGF Inhibitors Product Portfolio
6.5.5 Takeda Recent Developments/Updates
6.6 Merck KGaA
6.6.1 Merck KGaA Corporation Information
6.6.2 Merck KGaA Description and Business Overview
6.6.3 Merck KGaA C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Merck KGaA C-MET & HGF Inhibitors Product Portfolio
6.6.5 Merck KGaA Recent Developments/Updates
6.7 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck C-MET & HGF Inhibitors Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 Daiichi Sankyo
6.8.1 Daiichi Sankyo Corporation Information
6.8.2 Daiichi Sankyo Description and Business Overview
6.8.3 Daiichi Sankyo C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Daiichi Sankyo C-MET & HGF Inhibitors Product Portfolio
6.8.5 Daiichi Sankyo Recent Developments/Updates
6.9 GSK
6.9.1 GSK Corporation Information
6.9.2 GSK Description and Business Overview
6.9.3 GSK C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.9.4 GSK C-MET & HGF Inhibitors Product Portfolio
6.9.5 GSK Recent Developments/Updates
6.10 Bristol-Myers Squibb(BMS)
6.10.1 Bristol-Myers Squibb(BMS) Corporation Information
6.10.2 Bristol-Myers Squibb(BMS) Description and Business Overview
6.10.3 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product Portfolio
6.10.5 Bristol-Myers Squibb(BMS) Recent Developments/Updates
6.11 Roche
6.11.1 Roche Corporation Information
6.11.2 Roche C-MET & HGF Inhibitors Description and Business Overview
6.11.3 Roche C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Roche C-MET & HGF Inhibitors Product Portfolio
6.11.5 Roche Recent Developments/Updates
6.12 AVEO Pharmaceuticals
6.12.1 AVEO Pharmaceuticals Corporation Information
6.12.2 AVEO Pharmaceuticals C-MET & HGF Inhibitors Description and Business Overview
6.12.3 AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.12.4 AVEO Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio
6.12.5 AVEO Pharmaceuticals Recent Developments/Updates
6.13 Amgen
6.13.1 Amgen Corporation Information
6.13.2 Amgen C-MET & HGF Inhibitors Description and Business Overview
6.13.3 Amgen C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Amgen C-MET & HGF Inhibitors Product Portfolio
6.13.5 Amgen Recent Developments/Updates
6.14 AstraZeneca
6.14.1 AstraZeneca Corporation Information
6.14.2 AstraZeneca C-MET & HGF Inhibitors Description and Business Overview
6.14.3 AstraZeneca C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.14.4 AstraZeneca C-MET & HGF Inhibitors Product Portfolio
6.14.5 AstraZeneca Recent Developments/Updates
6.15 Mirati Therapeutics
6.15.1 Mirati Therapeutics Corporation Information
6.15.2 Mirati Therapeutics C-MET & HGF Inhibitors Description and Business Overview
6.15.3 Mirati Therapeutics C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Mirati Therapeutics C-MET & HGF Inhibitors Product Portfolio
6.15.5 Mirati Therapeutics Recent Developments/Updates
6.16 Eli Lilly
6.16.1 Eli Lilly Corporation Information
6.16.2 Eli Lilly C-MET & HGF Inhibitors Description and Business Overview
6.16.3 Eli Lilly C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Eli Lilly C-MET & HGF Inhibitors Product Portfolio
6.16.5 Eli Lilly Recent Developments/Updates
6.17 Johnson & Johnson
6.17.1 Johnson & Johnson Corporation Information
6.17.2 Johnson & Johnson C-MET & HGF Inhibitors Description and Business Overview
6.17.3 Johnson & Johnson C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Johnson & Johnson C-MET & HGF Inhibitors Product Portfolio
6.17.5 Johnson & Johnson Recent Developments/Updates
6.18 Eisai
6.18.1 Eisai Corporation Information
6.18.2 Eisai C-MET & HGF Inhibitors Description and Business Overview
6.18.3 Eisai C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Eisai C-MET & HGF Inhibitors Product Portfolio
6.18.5 Eisai Recent Developments/Updates
6.19 Hutchison MediPharma
6.19.1 Hutchison MediPharma Corporation Information
6.19.2 Hutchison MediPharma C-MET & HGF Inhibitors Description and Business Overview
6.19.3 Hutchison MediPharma C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Hutchison MediPharma C-MET & HGF Inhibitors Product Portfolio
6.19.5 Hutchison MediPharma Recent Developments/Updates
6.20 Kringle Pharmaceuticals
6.20.1 Kringle Pharmaceuticals Corporation Information
6.20.2 Kringle Pharmaceuticals C-MET & HGF Inhibitors Description and Business Overview
6.20.3 Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Kringle Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio
6.20.5 Kringle Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 C-MET & HGF Inhibitors Industry Chain Analysis
7.2 C-MET & HGF Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 C-MET & HGF Inhibitors Production Mode & Process
7.4 C-MET & HGF Inhibitors Sales and Marketing
7.4.1 C-MET & HGF Inhibitors Sales Channels
7.4.2 C-MET & HGF Inhibitors Distributors
7.5 C-MET & HGF Inhibitors Customers
8 C-MET & HGF Inhibitors Market Dynamics
8.1 C-MET & HGF Inhibitors Industry Trends
8.2 C-MET & HGF Inhibitors Market Drivers
8.3 C-MET & HGF Inhibitors Market Challenges
8.4 C-MET & HGF Inhibitors Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global C-MET & HGF Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global C-MET & HGF Inhibitors Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global C-MET & HGF Inhibitors Market Competitive Situation by Manufacturers in 2023
Table 4. Global C-MET & HGF Inhibitors Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global C-MET & HGF Inhibitors Sales Market Share by Manufacturers (2019-2024)
Table 6. Global C-MET & HGF Inhibitors Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global C-MET & HGF Inhibitors Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market C-MET & HGF Inhibitors Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of C-MET & HGF Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of C-MET & HGF Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of C-MET & HGF Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of C-MET & HGF Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global C-MET & HGF Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in C-MET & HGF Inhibitors as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global C-MET & HGF Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global C-MET & HGF Inhibitors Sales by Region (2019-2024) & (K Units)
Table 18. Global C-MET & HGF Inhibitors Sales Market Share by Region (2019-2024)
Table 19. Global C-MET & HGF Inhibitors Sales by Region (2025-2030) & (K Units)
Table 20. Global C-MET & HGF Inhibitors Sales Market Share by Region (2025-2030)
Table 21. Global C-MET & HGF Inhibitors Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global C-MET & HGF Inhibitors Revenue Market Share by Region (2019-2024)
Table 23. Global C-MET & HGF Inhibitors Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global C-MET & HGF Inhibitors Revenue Market Share by Region (2025-2030)
Table 25. North America C-MET & HGF Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America C-MET & HGF Inhibitors Sales by Country (2019-2024) & (K Units)
Table 27. North America C-MET & HGF Inhibitors Sales by Country (2025-2030) & (K Units)
Table 28. North America C-MET & HGF Inhibitors Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America C-MET & HGF Inhibitors Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe C-MET & HGF Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe C-MET & HGF Inhibitors Sales by Country (2019-2024) & (K Units)
Table 32. Europe C-MET & HGF Inhibitors Sales by Country (2025-2030) & (K Units)
Table 33. Europe C-MET & HGF Inhibitors Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe C-MET & HGF Inhibitors Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific C-MET & HGF Inhibitors Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific C-MET & HGF Inhibitors Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific C-MET & HGF Inhibitors Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific C-MET & HGF Inhibitors Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific C-MET & HGF Inhibitors Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America C-MET & HGF Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America C-MET & HGF Inhibitors Sales by Country (2019-2024) & (K Units)
Table 42. Latin America C-MET & HGF Inhibitors Sales by Country (2025-2030) & (K Units)
Table 43. Latin America C-MET & HGF Inhibitors Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America C-MET & HGF Inhibitors Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa C-MET & HGF Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa C-MET & HGF Inhibitors Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa C-MET & HGF Inhibitors Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa C-MET & HGF Inhibitors Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa C-MET & HGF Inhibitors Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global C-MET & HGF Inhibitors Sales (K Units) by Type (2019-2024)
Table 51. Global C-MET & HGF Inhibitors Sales (K Units) by Type (2025-2030)
Table 52. Global C-MET & HGF Inhibitors Sales Market Share by Type (2019-2024)
Table 53. Global C-MET & HGF Inhibitors Sales Market Share by Type (2025-2030)
Table 54. Global C-MET & HGF Inhibitors Revenue (US$ Million) by Type (2019-2024)
Table 55. Global C-MET & HGF Inhibitors Revenue (US$ Million) by Type (2025-2030)
Table 56. Global C-MET & HGF Inhibitors Revenue Market Share by Type (2019-2024)
Table 57. Global C-MET & HGF Inhibitors Revenue Market Share by Type (2025-2030)
Table 58. Global C-MET & HGF Inhibitors Price (US$/Unit) by Type (2019-2024)
Table 59. Global C-MET & HGF Inhibitors Price (US$/Unit) by Type (2025-2030)
Table 60. Global C-MET & HGF Inhibitors Sales (K Units) by Application (2019-2024)
Table 61. Global C-MET & HGF Inhibitors Sales (K Units) by Application (2025-2030)
Table 62. Global C-MET & HGF Inhibitors Sales Market Share by Application (2019-2024)
Table 63. Global C-MET & HGF Inhibitors Sales Market Share by Application (2025-2030)
Table 64. Global C-MET & HGF Inhibitors Revenue (US$ Million) by Application (2019-2024)
Table 65. Global C-MET & HGF Inhibitors Revenue (US$ Million) by Application (2025-2030)
Table 66. Global C-MET & HGF Inhibitors Revenue Market Share by Application (2019-2024)
Table 67. Global C-MET & HGF Inhibitors Revenue Market Share by Application (2025-2030)
Table 68. Global C-MET & HGF Inhibitors Price (US$/Unit) by Application (2019-2024)
Table 69. Global C-MET & HGF Inhibitors Price (US$/Unit) by Application (2025-2030)
Table 70. Exelixis Corporation Information
Table 71. Exelixis Description and Business Overview
Table 72. Exelixis C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Exelixis C-MET & HGF Inhibitors Product
Table 74. Exelixis Recent Developments/Updates
Table 75. Ipsen Corporation Information
Table 76. Ipsen Description and Business Overview
Table 77. Ipsen C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Ipsen C-MET & HGF Inhibitors Product
Table 79. Ipsen Recent Developments/Updates
Table 80. Pfizer Corporation Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Pfizer C-MET & HGF Inhibitors Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Novartis C-MET & HGF Inhibitors Product
Table 89. Novartis Recent Developments/Updates
Table 90. Takeda Corporation Information
Table 91. Takeda Description and Business Overview
Table 92. Takeda C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Takeda C-MET & HGF Inhibitors Product
Table 94. Takeda Recent Developments/Updates
Table 95. Merck KGaA Corporation Information
Table 96. Merck KGaA Description and Business Overview
Table 97. Merck KGaA C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Merck KGaA C-MET & HGF Inhibitors Product
Table 99. Merck KGaA Recent Developments/Updates
Table 100. Merck Corporation Information
Table 101. Merck Description and Business Overview
Table 102. Merck C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Merck C-MET & HGF Inhibitors Product
Table 104. Merck Recent Developments/Updates
Table 105. Daiichi Sankyo Corporation Information
Table 106. Daiichi Sankyo Description and Business Overview
Table 107. Daiichi Sankyo C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Daiichi Sankyo C-MET & HGF Inhibitors Product
Table 109. Daiichi Sankyo Recent Developments/Updates
Table 110. GSK Corporation Information
Table 111. GSK Description and Business Overview
Table 112. GSK C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. GSK C-MET & HGF Inhibitors Product
Table 114. GSK Recent Developments/Updates
Table 115. Bristol-Myers Squibb(BMS) Corporation Information
Table 116. Bristol-Myers Squibb(BMS) Description and Business Overview
Table 117. Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product
Table 119. Bristol-Myers Squibb(BMS) Recent Developments/Updates
Table 120. Roche Corporation Information
Table 121. Roche Description and Business Overview
Table 122. Roche C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Roche C-MET & HGF Inhibitors Product
Table 124. Roche Recent Developments/Updates
Table 125. AVEO Pharmaceuticals Corporation Information
Table 126. AVEO Pharmaceuticals Description and Business Overview
Table 127. AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. AVEO Pharmaceuticals C-MET & HGF Inhibitors Product
Table 129. AVEO Pharmaceuticals Recent Developments/Updates
Table 130. Amgen Corporation Information
Table 131. Amgen Description and Business Overview
Table 132. Amgen C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Amgen C-MET & HGF Inhibitors Product
Table 134. Amgen Recent Developments/Updates
Table 135. AstraZeneca Corporation Information
Table 136. AstraZeneca Description and Business Overview
Table 137. AstraZeneca C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. AstraZeneca C-MET & HGF Inhibitors Product
Table 139. AstraZeneca Recent Developments/Updates
Table 140. Mirati Therapeutics Corporation Information
Table 141. Mirati Therapeutics Description and Business Overview
Table 142. Mirati Therapeutics C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Mirati Therapeutics C-MET & HGF Inhibitors Product
Table 144. Mirati Therapeutics Recent Developments/Updates
Table 145. Eli Lilly Corporation Information
Table 146. Eli Lilly Description and Business Overview
Table 147. Eli Lilly C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Eli Lilly C-MET & HGF Inhibitors Product
Table 149. Eli Lilly Recent Developments/Updates
Table 150. Johnson & Johnson Corporation Information
Table 151. Johnson & Johnson Description and Business Overview
Table 152. Johnson & Johnson C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. Johnson & Johnson C-MET & HGF Inhibitors Product
Table 154. Johnson & Johnson Recent Developments/Updates
Table 155. Eisai Corporation Information
Table 156. Eisai Description and Business Overview
Table 157. Eisai C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 158. Eisai C-MET & HGF Inhibitors Product
Table 159. Eisai Recent Developments/Updates
Table 160. Hutchison MediPharma Corporation Information
Table 161. Hutchison MediPharma Description and Business Overview
Table 162. Hutchison MediPharma C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 163. Hutchison MediPharma C-MET & HGF Inhibitors Product
Table 164. Hutchison MediPharma Recent Developments/Updates
Table 165. Kringle Pharmaceuticals Corporation Information
Table 166. Kringle Pharmaceuticals Description and Business Overview
Table 167. Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 168. Kringle Pharmaceuticals C-MET & HGF Inhibitors Product
Table 169. Kringle Pharmaceuticals Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. C-MET & HGF Inhibitors Distributors List
Table 173. C-MET & HGF Inhibitors Customers List
Table 174. C-MET & HGF Inhibitors Market Trends
Table 175. C-MET & HGF Inhibitors Market Drivers
Table 176. C-MET & HGF Inhibitors Market Challenges
Table 177. C-MET & HGF Inhibitors Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of C-MET & HGF Inhibitors
Figure 2. Global C-MET & HGF Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global C-MET & HGF Inhibitors Market Share by Type in 2023 & 2030
Figure 4. Cabozantinib Product Picture
Figure 5. Crizotinib Product Picture
Figure 6. Others Product Picture
Figure 7. Global C-MET & HGF Inhibitors Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global C-MET & HGF Inhibitors Market Share by Application in 2023 & 2030
Figure 9. Hospital
Figure 10. Drug Store
Figure 11. Global C-MET & HGF Inhibitors Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global C-MET & HGF Inhibitors Market Size (2019-2030) & (US$ Million)
Figure 13. Global C-MET & HGF Inhibitors Sales (2019-2030) & (K Units)
Figure 14. Global C-MET & HGF Inhibitors Average Price (US$/Unit) & (2019-2030)
Figure 15. C-MET & HGF Inhibitors Report Years Considered
Figure 16. C-MET & HGF Inhibitors Sales Share by Manufacturers in 2023
Figure 17. Global C-MET & HGF Inhibitors Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest C-MET & HGF Inhibitors Players: Market Share by Revenue in 2023
Figure 19. C-MET & HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global C-MET & HGF Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America C-MET & HGF Inhibitors Sales Market Share by Country (2019-2030)
Figure 22. North America C-MET & HGF Inhibitors Revenue Market Share by Country (2019-2030)
Figure 23. U.S. C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe C-MET & HGF Inhibitors Sales Market Share by Country (2019-2030)
Figure 26. Europe C-MET & HGF Inhibitors Revenue Market Share by Country (2019-2030)
Figure 27. Germany C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific C-MET & HGF Inhibitors Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific C-MET & HGF Inhibitors Revenue Market Share by Region (2019-2030)
Figure 34. China C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Taiwan C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Philippines C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America C-MET & HGF Inhibitors Sales Market Share by Country (2019-2030)
Figure 45. Latin America C-MET & HGF Inhibitors Revenue Market Share by Country (2019-2030)
Figure 46. Mexico C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa C-MET & HGF Inhibitors Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa C-MET & HGF Inhibitors Revenue Market Share by Country (2019-2030)
Figure 51. Turkey C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. UAE C-MET & HGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of C-MET & HGF Inhibitors by Type (2019-2030)
Figure 55. Global Revenue Market Share of C-MET & HGF Inhibitors by Type (2019-2030)
Figure 56. Global C-MET & HGF Inhibitors Price (US$/Unit) by Type (2019-2030)
Figure 57. Global Sales Market Share of C-MET & HGF Inhibitors by Application (2019-2030)
Figure 58. Global Revenue Market Share of C-MET & HGF Inhibitors by Application (2019-2030)
Figure 59. Global C-MET & HGF Inhibitors Price (US$/Unit) by Application (2019-2030)
Figure 60. C-MET & HGF Inhibitors Value Chain
Figure 61. C-MET & HGF Inhibitors Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
